文章：

单克隆B细胞淋巴细胞增多症（MBL）的生物学、疾病进展及临床管理最新进展：血液癌症拦截研讨会委员会共识报告

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

原文发布日期：2025-08-29

DOI: 10.1038/s41408-025-01341-6

类型: Meeting Report

开放获取: 是

英文摘要：

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.
 

摘要翻译： 

2023年3月和2024年3月，一个国际专家小组在首届及第二届"拦截血液癌症"研讨会上召开会议，旨在更深入地认识前驱恶性血液病的诊断挑战、病理生理学及潜在治疗干预措施。本文报告了聚焦于单克隆B淋巴细胞增多症（MBL）/慢性淋巴细胞白血病（CLL）的会议内容概要，重点阐述了四个核心领域：MBL的生物学特性、MBL的临床意义、MBL的进展及从惰性CLL向侵袭性疾病的转化，以及早期CLL的治疗干预机遇。同时，我们概述了关键共识管理建议与研究目标。

原文链接：

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee